Diffusion of Tranexamic Acid to the Joint

Ahlberg, A; Eriksson, Olle; Kjellman, H

doi:10.3109/17453677608988725

Cited by 62 publications

(38 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients who had DVT or PE were diagnosed and treated in a timely manner and fully recovered. The peak time of venous thromboembolism is from 10 to 11 days after major orthopedic surgery, whereas the half‐life of TXA is only several hours, and it is nearly all excreted within 24 hours . One case of DVT was reported in the IA TXA‐alone group 5.5 months after the revision TKA.…”

Section: Discussionmentioning

confidence: 99%

Synergistic effects of intravenous and intra‐articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study

Yuan

Wang

et al. 2018

Transfusion

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic effects of intravenous and intra‐articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study

Yuan

Wang

et al. 2018

Transfusion

View full text Add to dashboard Cite

show abstract

“…When tranexamic acid is administered intravenously, it is widely distributed through the extracellular and intracellular compartments [34]. When a high dose of systemic tranexamic acid is administered, the drug rapidly diffuses into the joint and has a biological half-life of approximately 3 hours [2]. To address the potential risk of thromboembolism with high doses of tranexamic acid, low-dose tranexamic acid has been topically used in dental surgery [42], cardiac surgery [1,13], and spine surgery [21].…”

Section: Discussionmentioning

confidence: 99%

Topical Tranexamic Acid Reduces Blood Loss and Transfusion Rates Associated With Primary Total Hip Arthroplasty

Chang

Chen

et al. 2014

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Systemic tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical tranexamic acid in THA has only recently been characterized in a small number of studies. Questions/purposes The purpose of this study was to compare (1) the greatest hemoglobin decrease after surgery;(2) transfusion rates; and (3) symptomatic thromboembolic events among patients undergoing THA who did and did not receive topical tranexamic acid.

show abstract

“…Nonetheless, Ahlberg et al . reported that the drug diffuses rapidly through the synovial membrane, which allows for an immediate anti-hemorrhagic effect during TKA [28]. In a recent TKA study [29], five different intravenous drug regimens were tested using 10 mg/kg doses: (1) intraoperative single-dose; (2) double-dose, intraoperative and postoperative (3 hours after the first dose); (3) double-dose, preoperative (20 minutes before tourniquet inflation) and intraoperative; (4) triple-dose regimens, preoperative, intraoperative and postoperative; and (5) placebo.…”

Section: Discussionmentioning

confidence: 99%

Tranexamic Acid Reduces Blood Loss and Transfusion in Patients Undergoing Total Knee Arthroplasty without Tourniquet: A Prospective Randomized Controlled Trial

Bidolegui¹,

Arce²,

Lugones³

et al. 2014

TOORTHJ

View full text Add to dashboard Cite

Introduction : Blood loss during and after total knee arthroplasty (TKA) can lead to substantial morbidity and the need for blood transfusions. There are several methods to minimize blood loss and to decrease transfusion rates in patients undergoing TKA. Tranexamic acid is an antifibrinolytic agent with known efficacy for achieving these goals. Currently, many surgeons are performing TKA without the use of tourniquet. Consequently, the aim of the study is to evaluate whether tranexamic acid reduces blood loss during and after TKA without the adjunctive use of above-the-knee tourniquet.Methods : We performed a prospective randomized controlled trial (1:1 fashion) on the use of tranexamic acid versus placebo in 50 patients undergoing TKA (without tourniquet). The treatment group received two (preoperative and postoperative) 15 mg/kg doses. The primary endpoint was blood transfusion rate. We collected data about demographic and procedural characteristics, hemoglobin and hematocrit values, drain blood loss at 24 hours as well as adverse events.Results : There were no transfusions in the treatment group, whereas 32% of the control group required transfusion (p<0.01). The treatment group had higher hematocrit and hemoglobin levels at 24, 48 and 72 hours after surgery (all p<0.01) and lower drain loss at 24hours (363.4±141 vs 626±260ml, p=<0,001). There were no in-hospital or six-month thromboembolic complications.Discussion : A double-dose of tranexamic acid was safe and effective, reducing blood loss and preventing the need of blood transfusion in patients undergoing TKA without above-the-need tourniquet.

show abstract

Diffusion of Tranexamic Acid to the Joint

Cited by 62 publications

References 5 publications

Synergistic effects of intravenous and intra‐articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study

Synergistic effects of intravenous and intra‐articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study

Topical Tranexamic Acid Reduces Blood Loss and Transfusion Rates Associated With Primary Total Hip Arthroplasty

Tranexamic Acid Reduces Blood Loss and Transfusion in Patients Undergoing Total Knee Arthroplasty without Tourniquet: A Prospective Randomized Controlled Trial

Contact Info

Product

Resources

About